Roundtable Discussion: Evolving Preclinical & Clinical Trial Design for Cannabinoid Drug Development
Time: 11:30 am
day: Day Two
Details:
- Why have there been relatively few approvals to date of cannabinoid and CB1 and CB2 targeting drugs?
- What promising potential of cannabinoids is there beyond their approved use in conditions like multiple sclerosis, neuropathic pain, and obesity?
- How can we choose the right active ingredient, taking into account safety, efficacy, and therapeutic benefits?
- How can we design trials that prioritize patient experience and compliance?
- How can we address trial complications arising from diverse standards of care across different geographical regions?
Moderator Feedback & Audience Debate
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.
